TearClear files IND to begin clinical trial for glaucoma candidate
Click Here to Manage Email Alerts
TearClear has filed an investigational new drug application for its first glaucoma drop candidate.
The company plans to initiate a clinical trial to evaluate TC-002 latanoprost ophthalmic solution 0.005%. The solution will be preservative free “to prevent long-term deleterious effects on the eye,” according to a press release.
“We are confident that improving the health of the ocular surface matters,” TearClear CEO Stuart Raetzman said in the release. “Responding to that unmet need has propelled us to this important milestone and it is what drives us to expand our efforts for other glaucoma therapies and to important therapies beyond glaucoma that intersect with [ocular surface disease].”
Editor’s note: This article has been updated from its original version to provide more clarity about the application.
Read more about
Click Here to Manage Email Alerts